Medical Research
(H05)
990 on File
FUTURE OF HEALTH INC
Financial strength (30%)
69/100
Reliability (20%)
40/100
Effectiveness (25%)
66/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2024
$803K
Total Revenue
$601K
Total Expenses
$126K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
92.9%
Fundraising Efficiency
N/A
Operating Reserve
2.52x
Liability-to-Asset
67.7%
Revenue Diversification
100.0%
Compared with Peers
FY 2024
Compared with 726 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
92.9% | 84.5% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
7.1% | 11.4% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
2.5 mo | 13.4 mo |
P10P90
|
Bottom quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
67.7% | 0.4% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
100.0% | 93.3% |
P10P90
|
Bottom quarter |
|
Revenue growth
Year over year revenue growth
|
22.6% | 9.1% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
27.5% | 8.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
25.2% | 1.8% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $803K | $601K | $126K | 92.9% | 0 |
| 2023 | $655K | $471K | $292K | 94.6% | 0 |
| 2022 | $300K | $192K | $108K | 99.5% | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.